TP53 and outcome in DLBCL: not only the coding region.

TP53 and outcome in DLBCL: not only the coding region.

Blood (2013-06-01)

Fabrice Jardin, Bertrand Coiffier

RESUMEN

In this issue of Blood, Li et al report mutations in the 3′ untranslated region (3′UTR) of TP53 that modify the expression of p53 and thus its effect on response to therapy in diffuse large B-cell lymphoma (DLBCL) patients.

MATERIALES

Número de producto

Marca

Descripción del producto

D1515

Sigma-Aldrich

Doxorrubicina hydrochloride, 98.0-102.0% (HPLC)

C0768

Sigma-Aldrich

Cyclophosphamide monohydrate, bulk package

44583

Sigma-Aldrich

Doxorrubicina hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)

P6254

Sigma-Aldrich

Prednisona, ≥98%

D2975000

Doxorrubicina hydrochloride, European Pharmacopoeia (EP) Reference Standard

C7397

Sigma-Aldrich

Cyclophosphamide monohydrate, ISOPAC^®

V8879

Sigma-Aldrich

Vincristine sulfate salt, 95.0-105.0% (HPLC), powder or crystals

PHR1042

Supelco

Prednisona, Pharmaceutical Secondary Standard; Certified Reference Material

V8388

Sigma-Aldrich

Vincristine sulfate, meets USP testing specifications

V0400000

Vincristine sulfate, European Pharmacopoeia (EP) Reference Standard